Leiter, A. et al. The worldwide burden of lung most cancers: Present standing and future developments. Nat. Rev. Clin. Oncol. 20(9), 624–639 (2023).
Sung, H. et al. World most cancers statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 nations. CA Most cancers J. Clin. 71(3), 209–249 (2021).
Lemjabbar-Alaoui, H. et al. Lung most cancers: Biology and remedy choices. Biochim. Biophys. Acta 1856(2), 189–210 (2015).
Rizzo, A. Figuring out optimum first-line remedy for superior non-small cell lung carcinoma with excessive PD-L1 expression: A matter of debate. Br. J. Most cancers 127(8), 1381–1382 (2022).
Rizzo, A. et al. Hypertransaminasemia in most cancers sufferers receiving immunotherapy and immune-based mixtures: The MOUSEION-05 examine. Most cancers Immunol. Immunother. 72(6), 1381–1394 (2023).
Guven, D. C. et al. The affiliation between albumin ranges and survival in sufferers handled with immune checkpoint inhibitors: A scientific assessment and meta-analysis. Entrance. Mol. Biosci. 9, 1039121 (2022).
Zheng, Y. et al. Particular intestine microbiome signature predicts the early-stage lung most cancers. Intestine Microbes 11(4), 1030–1042 (2020).
Zeng, H. et al. Altering most cancers survival in China throughout 2003–15: A pooled evaluation of 17 population-based most cancers registries. Lancet Glob. Well being 6(5), e555–e567 (2018).
Goldstraw, P. et al. The IASLC lung most cancers staging mission: proposals for revision of the TNM stage groupings within the forthcoming (Eighth) version of the TNM classification for lung most cancers. J. Thorac. Oncol. 11(1), 39–51 (2016).
Paci, E. et al. Mortality, survival and incidence charges within the ITALUNG randomized lung most cancers screening trial. Thorax 72(9), 825–831 (2017).
Becker, N. et al. Lung most cancers mortality discount by LDCT screening-Outcomes from the randomized German LUSI trial. Int. J. Most cancers 146(6), 1503–1513 (2020).
De Koning, H. J. et al. Diminished lung-cancer mortality with quantity CT screening in a randomized trial. N. Engl. J. Med. 382(6), 503–513 (2020).
Zhao, R. et al. Can deep studying enhance picture high quality of low-dose CT: a potential examine in interstitial lung illness. Eur. Radiol. 32(12), 8140–8151 (2022).
Xu, X. et al. Feasibility of low-dose CT with spectral shaping and third-generation iterative reconstruction in evaluating interstitial lung illnesses related to connective tissue illness: An intra-individual comparability examine. Eur. Radiol. 29(9), 4529–4537 (2019).
Subramanian, J. et al. Distinctive traits of non-small cell lung most cancers (NSCLC) within the younger: A surveillance, epidemiology, and finish outcomes (SEER) evaluation. J. Thorac. Oncol. 5(1), 23–28 (2010).
Tanaka, Ok. et al. Distinctive prevalence of oncogenic genetic alterations in younger sufferers with lung adenocarcinoma. Most cancers. 123(10), 1731–1740 (2017).
Sacher, A. G. et al. Affiliation between youthful age and targetable genomic alterations and prognosis in non-small cell lung most cancers. JAMA Oncol. 2(3), 313–320 (2016).
Bak, S. H. et al. Quantitative CT scanning evaluation of pure ground-glass opacity nodules predicts additional CT scanning change. Chest 149(1), 180–191 (2016).
Zhang, Y. et al. The outcomes of low-dose computed tomography as an everyday well being examination amongst Chinese language hospital staff. J. Thorac. Cardiovasc. Surg. 160(3), 824-831.e4 (2020).
Miura, A. et al. Completely different sizes of centrilobular ground-glass opacities in chest high-resolution computed tomography of sufferers with pulmonary veno-occlusive illness and sufferers with pulmonary capillary hemangiomatosis. Cardiovasc. Pathol. 22(4), 287–293 (2013).
Travis, W. D. et al. Worldwide affiliation for the examine of lung most cancers/American Thoracic Society/European Respiratory Society: worldwide multidisciplinary classification of lung adenocarcinoma: government abstract. Proc. Am. Thorac. Soc. 8(5), 381–385 (2011).
Zhu, W. et al. Genetic traits of lung adenocarcinoma with ground-glass opacity element. J. Thorac. Dis. 15(11), 6106 (2021).
Qu, R. et al. Medical options and surgical outcomes of younger sufferers with lung adenocarcinoma manifesting as floor glass opacity. Entrance. Oncol. 12, 979522 (2022).
Wang, J. et al. Medical traits and prognosis of ground-glass opacity nodules in younger sufferers. J. Thorac Dis. 11(2), 557–563 (2019).
Nicholson, A. G. et al. The 2021 WHO classification of lung tumors: Affect of advances since 2015. J. Thorac. Oncol. 17(3), 362–387 (2022).
Shrestha, B. et al. The declaration of Helsinki on medical analysis involving human topics: a assessment of seventh revision. J. Nepal Well being Res. Counc. 17(4), 548–552 (2019).
Lee, H. Y. & Lee, Ok. S. Floor-glass opacity nodules: Histopathology, imaging analysis, and medical implications. J. Thorac. Imaging 26(2), 106–118 (2011).
Bak, S. H. et al. Quantitative CT scanning evaluation of pure ground-glass opacity nodules predicts additional CT scanning change. Chest 149(1), 180–191 (2016).
Raz, D. J. et al. Present ideas in bronchioloalveolar carcinoma biology. Clin. Most cancers Res. 12(12), 3698–3704 (2006).
Mao, W. et al. Germline mutation analyses of malignant floor glass opacity nodules in nonsmoking lung adenocarcinoma sufferers. PeerJ 9, e12048 (2021).
Malhotra, J. et al. Threat components for lung most cancers worldwide. Eur. Resp. J. 48(3), 889–902 (2016).
Cai, L. et al. The genomic panorama of younger and previous lung most cancers sufferers highlights age-dependent mutation frequencies and medical actionability in younger sufferers. Int. J. Most cancers 149(4), 883–892 (2021).
Garrana, S. H. et al. Medical and imaging options of non–small-cell lung most cancers in younger sufferers. Clin. Lung Most cancers 22(1), 23–31 (2021).
Suidan, A. M. et al. Lung most cancers in younger sufferers: increased charge of driver mutations and mind involvement, however higher survival. J. Glob. Oncol. 5, 1 (2019).
Migliore, M. et al. Floor glass opacities administration within the lung most cancers screening period. Ann. Transl. Med. 6(5), 90 (2018).
Qin, Y. et al. Medical traits of resected solitary ground-glass opacities: Comparability between benign and malignant nodules. Thorac. Most cancers 11(10), 2767–2774 (2020).
Wang, L. et al. Lymph node metastasis in medical stage IA peripheral lung most cancers. Lung Most cancers 90(1), 41–46 (2015).
Osarogiagbon, R. U. et al. Survival implications of variation within the thoroughness of pathologic lymph node examination in American Faculty of Surgeons Oncology Group Z0030 (Alliance). Ann. Thorac. Surg. 102(2), 363–369 (2016).
Zhang, Z. et al. Exploration of lymph node metastasis and applicable lymph node dissection modes in sufferers with medical stage I non-small cell lung most cancers. Chin. J. Oncol. 36(7), 536–540 (2014).
